MétaCan
Menu
Back to cohort
Record W4412012626 · doi:10.3389/fmed.2025.1593933

Fingolimod synergizes with anti-PD-1 radioimmunotherapy in an experimental multiple sclerosis model through enhanced lymph node retention and CD8+ T cell depletion

2025· article· en· W4412012626 on OpenAlexaff
Connor Frank, Kevin J. Allen, Wojciech Dawicki, Michael C. Levin, Ekaterina Dadachova

Bibliographic record

VenueFrontiers in Medicine · 2025
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsCameco (Canada)University of Saskatchewan
Fundersnot available
KeywordsMedicineMultiple sclerosisFingolimodExperimental autoimmune encephalomyelitisImmune systemRadioimmunotherapyImmunologyCD8PharmacologyAntibody

Abstract

fetched live from OpenAlex

Introduction Multiple sclerosis (MS) is a chronic neurodegenerative autoimmune disease caused by inappropriate activation of the immune system that targets central nervous system antigens, such as myelin. Some MS therapies control the disease through the depletion of CD20+ B cells and the sequestration of T lymphocytes in lymph nodes. A targeted approach aimed at depleting only activated T lymphocytes, which play a key role in disease progression, would be optimal. Programmed cell death protein 1 (PD-1) is an inhibitory receptor expressed on exhausted and recently activated T cells. We have previously reported success with [177Lu]Lu-anti-PD-1 (177Lu-αPD-1) radioimmunotherapy (RIT) as a standalone treatment in experimental autoimmune encephalomyelitis (EAE), which is the most common preclinical model of MS. In this study, we present the synergistic effect of fingolimod (FTY720/Gilenya™) in combination with [177Lu]Lu-αPD-1 in EAE. Methods [177Lu]Lu-αPD-1 and [111In]In-αPD-1 were prepared by conjugating a commercial anti-murine PD-1 antibody with a DOTA bifunctional chelating agent. Therapy using [177Lu]Lu-αPD-1 ± FTY720 was initiated at the EAE symptom onset in MOG 35–55 immunized C57Bl/6 mice. ImmunoSPECT/CT imaging utilizing [111In]In-αPD-1 was performed with or without FTY720 administration at the symptom onset in EAE mice. Flow cytometry was performed on spinal cord mononuclear cells isolated from EAE mice 7 days post treatment with RIT ± FTY720. Results [177Lu]Lu-αPD-1 in combination with FTY720 administration significantly reduced long-term paralysis in EAE mice. ImmunoSPECT/CT imaging revealed enhanced lymph node retention of [111In]In-αPD-1 antibody in conjugation with FTY720, corresponding to the presence of activated lymphocytes in lymph nodes. Flow cytometry performed on isolated spinal cord mononuclear cells demonstrated a significant reduction in CD8+ T cell counts in the spinal cords of animals treated with [177Lu]Lu-αPD-1 and [177Lu]Lu-αPD-1 + FTY720. Immunofluorescent microscopy of thoracic spinal cord sections from treated animals demonstrated reduced demyelination and moderate infiltration of CD3+ lymphocytes in the [177Lu]Lu-αPD-1 + FTY720 group at study termination. Conclusion [177Lu]Lu-αPD-1-targeted radioimmunotherapy was synergistically enhanced utilizing the approved MS therapeutic FTY720 through increased lymph node retention and irradiation of activated T lymphocytes. This study paves the way for the application of PD-1+ T cell-targeted radioimmunotherapy as a potential theranostic agent for MS.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.268
Teacher spread0.246 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueFrontiers in MedicineSame topicCancer Immunotherapy and BiomarkersFrench-language works237,207